An Introduction to NAYA Biosciences with CEO Dr. Daniel Teper

首席执行官Daniel Teper博士对NAYA Biosciences的介绍

Managing unprecedented medical innovation in an era of financial market volatility

在金融市场波动时代管理前所未有的医疗创新

Increasing patient access to breakthrough treatments in oncology, regenerative medicine, and fertility

增加患者获得肿瘤学，再生医学和生育方面突破性治疗的机会

SARASOTA, Fla. and AVENTURA, Fla., Oct. 27, 2023 /PRNewswire/ -- INVO Bioscience ('INVO') and NAYA Biosciences ('NAYA'), two companies which recently signed a definitive merger agreement, today announced that NAYA CEO Dr. Daniel Teper will present at Tribe Public's Webinar Presentation and Q&A Event, titled 'Accelerating Biotech Value Creation' . The event is scheduled to begin at 8:30AM PST/11:30AM EST on Tuesday, October 31, 2023.

佛罗里达州萨拉索塔和佛罗里达州安万图拉，2023年10月27日/PRNewswire/-INVO-Bioscience（'INVO'）和NAYA-Biosciences（'NAYA'），两家公司最近签署了最终的合并协议，今天宣布NAYA首席执行官Daniel Teper博士将出席部落公众的网络研讨会和问答活动，题为“加速生物技术价值创造”。活动定于2023年10月31日星期二上午8:30 PST/11:30开始。

To register to join the complimentary event, please visit the Tribe Public LLC at NAYAOCT3123.TribePublic.com..

要注册参加免费活动，请访问NAYAOCT3123.TribePublic.com上的Tribe Public LLC。。

Continue Reading

继续阅读

Free Registration Is Now Open For Tribe Public’s CEO and Q&A Presentation Webinar Event 'Accelerating Biotech Value Creation' Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023

2023年10月31日星期二，部落公共首席执行官兼问答演示网络研讨会活动“加速生物技术价值创造”，免费注册

NAYA Biosciences Inc. (PRNewsfoto/INVO Bioscience, Inc.)

NAYA Biosciences Inc.（PRNewsfoto/INVO Bioscience，Inc.）

NAYA Biosciences is building a group of agile, disruptive, high-growth companies dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative medicine.  NAYA's capabilities in biology, cell and gene therapy, and artificial intelligence (AI) provide a synergistic platform for the accelerated clinical development and commercialization of these breakthrough treatments..

奈亚生物科学公司正在建立一组敏捷，破坏性，高增长的公司，致力于增加患者在肿瘤学，生育和再生医学领域获得生命转化治疗的机会。奈亚在生物学，细胞和基因治疗以及人工智能（AI）方面的能力为这些突破性治疗的加速临床开发和商业化提供了协同平台。。

Dr. Teper is the Founder, Chairman, and Chief Executive Officer of NAYA Biosciences. He has over 30 years of leadership experience as a biopharma entrepreneur, corporate executive, and management consultant.

Teper博士是NAYA Biosciences的创始人，主席和首席执行官。作为生物制药企业家，公司执行官和管理顾问，他拥有30多年的领导经验。

Previously, Dr. Teper was the Chairman & CEO of Cytovia Therapeutics, where he remains Chairman of the Board. From 2011 to 2017, he was the CEO of Immune Pharmaceuticals, which he listed on NASDAQ. He previously served as New York-based Managing Partner (Head of North America) at Bionest Partners, now Accenture, where he advised companies on corporate strategy and business development.

此前，Teper博士是Cytovia Therapeutics的主席兼首席执行官，他仍然是董事会主席。从2011年到2017年，他是他在纳斯达克上市的Immune Pharmaceuticals的首席执行官。他以前曾在Bionest Partners（现为Accenture）担任纽约的管理合作伙伴（北美负责人），在那里他为公司提供公司战略和业务发展方面的咨询。

He was previously a Partner at ISO Healthcare Group, now Deloitte, in New York. Dr. Teper helped drive the accelerated growth of Softwatch, a pioneer digital health company, as senior vice president of sales and business development. He also served as global president of Havas Health, advising companies on global launches of major new drugs in multiple disease areas.

他以前是纽约州Deloitte的ISO Healthcare Group的合作伙伴。Teper博士帮助推动了作为销售和业务发展高级副总裁的先驱数字健康公司Softwatch的加速发展。他还担任哈瓦斯健康全球总裁，为全球在多个疾病领域推出主要新药的公司提供咨询。

Dr. Teper started his career at Novartis in Basel and then in the US, where he held management responsibilities in sales and marketing and as head of cardiovascular, new product development. Dr. Teper held general management positions in Europe at GlaxoSmithKline and Sanofi. He was the co-founder and CEO of Wintec Pharma, a European specialty pharmaceutical company focused on anti-infectives and dermatology, which he went on to sell.

Teper博士在巴塞尔的诺华公司开始了职业生涯，然后在美国担任销售和营销管理责任，并担任心血管新产品开发负责人。Teper博士在欧洲葛兰素史克和赛诺菲担任一般管理职位。他是Wintec Pharma的联合创始人兼首席执行官，Wintec Pharma是一家专注于抗感染和皮肤病学的欧洲专业制药公司，他继续销售。

Dr. Teper co-founded Novagali, an ophthalmology specialty pharma later listed on EuroNext Paris and acquired by Japan's Santen.He holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD, where he was the J. Salmon scholar.Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at [email protected] or share their questions via the ZOOM chat feature during the event.

Teper博士共同创立了Novagali，这是一家眼科专业制药公司，后来在EuroNext Paris上市并被日本Santen收购。他拥有Paris-XI大学药学博士学位和INSEAD MBA，他是J.Salmon学者。一旦注册，参与者可以开始将他们的问题转发给首席执行官[电子邮件保护]的部落公众，或在事件期间通过缩放聊天功能分享他们的问题。

Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.ABOUT NAYA BiosciencesNAYA Biosciences is building a grou.

Tribe Public的管理成员John F.Heerdink，Jr.将主持活动并将所有问题传达给管理层。关于NAYA BiosciencesNAYA Biosciences正在建设一个集团。